High costs and the novelty and complexity of new therapies such as gene therapy present social determinants of health and ...

Cost is a barrier to care for chronic and rare diseases, so financial assistance is way to lower that barrier and help people ...

A decision is expected in the fourth quarter of 2025.

In January 2023, the Brukinsa, a next-generation BTK inhibitor, received FDA approval for chronic lymphocytic leukemia (CLL).

In mice with human Merkel cell carcinoma, pyrvinium pamoate significantly reduced tumor growth, potentially offering a new ...

Digital pharmacy solutions can help brick and mortar locations become more efficient, according to Sarah Thomas, VP of sales ...

Cigna Healthcare’s medical care ratio increased to 82.2% in the first quarter compared with 79.9% in the first quarter of ...